If a tumor is positive for a KRAS mutation, no further molecular testing is required, and treatment recommendations will focus on chemotherapy because tumors harboring somatic mutations in KRAS, which encodes a GTPase downstream of EGFR, display greater resistance to these targeted drugs. The gene discussed is KRAS; the disease is neoplasm.